Effects of tapering doses of oral prednisone on viral load among HIV-infected patients with unexplained weight loss

AIDS Res Hum Retroviruses. 1997 Nov 20;13(17):1533-7. doi: 10.1089/aid.1997.13.1533.

Abstract

In an exploratory study of virologic and immunomodulatory effects of corticosteroid therapy for wasting syndrome, four HIV-infected adults with recent unexplained weight loss were given tapering doses of prednisone over a 2-month period. Serum neopterin and TNF receptor II levels decreased from baseline after 7 days. An antiretroviral effect was observed initially, peaking on days 14-21 (mean change in HIV-1 branched chain DNA assay on day 21 of -0.52 log10; mean change, from baseline to nadir for each individual, of -0.63 log10); subsequent bDNA levels returned toward baseline as prednisone was tapered. No patient lost weight and there was a mean weight gain of 3.5 kg. Anecdotal reports of corticosteroid benefits in the wasting syndrome may result in part from decreased T cell activation leading to decreased HIV replication, an effect that may be self-limited or that may occur only at higher prednisone doses. Studies involving more targeted immunomodulatory agents for wasting syndrome are warranted.

Publication types

  • Clinical Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • CD4 Lymphocyte Count
  • Dose-Response Relationship, Drug
  • Female
  • HIV Wasting Syndrome / drug therapy*
  • HIV Wasting Syndrome / immunology
  • Humans
  • Male
  • Neopterin / metabolism
  • Prednisone / administration & dosage*
  • Prednisone / adverse effects
  • Prednisone / therapeutic use
  • Weight Loss*

Substances

  • Neopterin
  • Prednisone